IBox

Slenergy Rewarded Great Success in Genera 2024

Retrieved on: 
火曜日, 2月 27, 2024
EV, Internet of things, IBox, Exhibition, Carbon, C&I, Genus, MES

commented a visitor at the Innovation Gallery in front of Slenergy's iShare-Home One-Stop Residential Smart Energy Solution stand during Genera 2024 – Energy and Environment International Trade Fair, in Madrid on February 6.

Key Points: 
  • commented a visitor at the Innovation Gallery in front of Slenergy's iShare-Home One-Stop Residential Smart Energy Solution stand during Genera 2024 – Energy and Environment International Trade Fair, in Madrid on February 6.
  • Slenergy, a leading innovator in the renewable energy industry, shone brightly at the Spanish biggest energy fair with its flagship products for the European market.
  • This year, Slenergy brought its whole-line inverters to the Genera exhibition, covering both residential and C&I aspects.
  • The upgraded iShare-Home system, launched during GENERA 2024 in Madrid, offers a One-Stop smart solution with more diversified components according to customers' demands.

Slenergy Launches 2024 with Upgraded iShare-Home Solar Kit

Retrieved on: 
月曜日, 1月 22, 2024
City, Electricity, Exhibition, Investment, Guidance, EV, Internet of things, Partner, IBox, Renewable energy

MADRID, Jan. 22, 2024 /PRNewswire/ -- Slenergy, a leading innovator in the renewable energy industry, is set to captivate once again the European residential solar market with its upgraded iShare-Home One-Stop Residential Smart Energy Solution.

Key Points: 
  • MADRID, Jan. 22, 2024 /PRNewswire/ -- Slenergy, a leading innovator in the renewable energy industry, is set to captivate once again the European residential solar market with its upgraded iShare-Home One-Stop Residential Smart Energy Solution.
  • Building on its remarkable success during 2023, the standardized solar kit will debut at the GENERA 2024 – Energy and Environment International Trade Fair, in Madrid on February 6.
  • After its introduction, the one-stop solar kit received a warm reception, leading to thousands of installations in German, Spanish and Italian households.
  • The upgraded version of the single-window purchase solar kit, offering one-stop delivery and full-process service, showcases significant advancements.

Slenergy Launches Tailored iShare-Home One-Stop Solar Solution for Italian Households

Retrieved on: 
月曜日, 10月 16, 2023
Carbon, Solare, Bloomberg, IBox, Light, Renewable energy, Television

At this event, Slenergy introduced its innovative residential energy solution, iShare-Home, aiming at helping Italian households reduce energy costs, achieve energy independence, and minimize their carbon footprint.

Key Points: 
  • At this event, Slenergy introduced its innovative residential energy solution, iShare-Home, aiming at helping Italian households reduce energy costs, achieve energy independence, and minimize their carbon footprint.
  • Esteemed guests from the new energy industry and valued partners from various regions of Italy graced the event, marking an important achievement for Slenergy.
  • The standout moment of the event was the highly anticipated introduction of the iShare-Home tailor-made for the Italian market.
  • Acknowledging the importance of the Italian solar market, Slenergy introduced special promotional incentives during the event.

Slenergy Launches Tailored iShare-Home One-Stop Solar Solution for Italian Households

Retrieved on: 
月曜日, 10月 16, 2023
Multimedia, Carbon, Solare, Bloomberg, IBox, Light, Renewable energy, Television

At this event, Slenergy introduced its innovative residential energy solution, iShare-Home, aiming at helping Italian households reduce energy costs, achieve energy independence, and minimize their carbon footprint.

Key Points: 
  • At this event, Slenergy introduced its innovative residential energy solution, iShare-Home, aiming at helping Italian households reduce energy costs, achieve energy independence, and minimize their carbon footprint.
  • Esteemed guests from the new energy industry and valued partners from various regions of Italy graced the event, marking an important achievement for Slenergy.
  • iShare-Home is a one-stop solution characterized by standardized system design, modular product design, easy installation and smart energy management.
  • Acknowledging the importance of the Italian solar market, Slenergy introduced special promotional incentives during the event.

C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

Retrieved on: 
水曜日, 12月 21, 2022
TTC, Serum, European Medicines Agency, Drug development, Biomarker, EGFR, Banff, Patient, Proteinuria, IST, IBox, Physician, Critical Path Institute, Kidney, EMA, Survival, Transplant, Pharmaceutical industry, Eledone palari

IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion for the iBox Scoring System as a novel secondary efficacy endpoint for kidney transplant clinical trials through the European Medicines Agency's (EMA) qualification of novel methodologies for drug development.

Key Points: 
  • IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion for the iBox Scoring System as a novel secondary efficacy endpoint for kidney transplant clinical trials through the European Medicines Agency's (EMA) qualification of novel methodologies for drug development.
  • This novel secondary endpoint supports the evaluation of new immunosuppressive therapy (IST) applications for the prevention of kidney transplant rejection and is the first EMA qualified endpoint for any transplant indication.
  • “We are proud to be collaborators with the Transplant Therapeutic Consortium and congratulate it on receiving this important qualification opinion from the EMA,” said David Alexandre C. Gros, M.D., Chief Executive Officer of Eledon.
  • We look forward to incorporating the iBox Scoring System as an endpoint in our trials, as we continue our development of tegoprubart for the prevention of allograft rejection in patients receiving a kidney transplant.”

CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System

Retrieved on: 
木曜日, 10月 27, 2022
Health Technology, Genetics, Health, Surgery, Transplant, Annual report, EGFR, Leadership, IBox, Therapy, Patient, Receipt, Caregiver, Nasdaq, CEO, EMA, Proteinuria, European Medicines Agency, SEC, Precision medicine, System, Dentistry, Collaboration

CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today congratulates C-Paths Transplant Therapeutics Consortium and the Paris Transplant Group for their leadership in gaining European Medicine Agency (EMA) draft qualification1 for the iBox Scoring System as a secondary endpoint in kidney transplant clinical trials.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today congratulates C-Paths Transplant Therapeutics Consortium and the Paris Transplant Group for their leadership in gaining European Medicine Agency (EMA) draft qualification1 for the iBox Scoring System as a secondary endpoint in kidney transplant clinical trials.
  • CareDx congratulates C-Paths Transplant Therapeutics Consortium and the Paris Transplant Group for receiving this regulatory approval for the iBox Scoring System.
  • We are proud to be long-standing collaborators with the incredible teams at the Transplant Therapeutics Consortium and the Paris Transplant Group and look forward to working together to drive the next wave of transplant innovation.
  • This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with iBox Scoring System, the receipt of EMA draft qualification by C-Path's Transplant Therapeutics Consortium and the Paris Transplant Group (Receipt of Qualification), and CareDxs collaborations with C-Path's Transplant Therapeutics Consortium and the Paris Transplant Group (the Collaborations).

C-Path's Transplant Therapeutics Consortium receives EMA Draft Qualification Opinion for the iBox Scoring System

Retrieved on: 
金曜日, 10月 14, 2022
AST, U.S. Department of Defense Strategy for Operating in Cyberspace, TTC, Health care, Therapy, European Medicines Agency, Life, Dialysis, IBox, Review, Government, SOC, EMA, Ammonia, Food and Drug Administration, Proteinuria, Banff, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IST, Patient, Drug development, Society, Standard of care, HHS, Transplant, Multimedia, Partnership, Unitary state, Food, Transplant surgeon, Asahi Kasei, CEO, Biopsy, Critical Path Institute, Office of Inspector General, U.S. Department of Health and Human Services, FDA, Solution, EGFR, Pharmaceutical industry, Dentistry, Veloxis Pharmaceuticals

CARY, N.C., Oct. 14, 2022 /PRNewswire/ -- Critical Path Institute (C-Path) announced October 13, 2022 that its Transplant Therapeutic Consortium (TTC), of which Veloxis Pharmaceuticals is a member, received a draft qualification opinion for the iBox Scoring System through the European Medicines Agency's (EMA) qualification of novel methodologies for drug development. This significant qualification means that the iBox Scoring System, which supports the evaluation of novel immunosuppressive therapy (IST) applications with EMA, will soon be available to be used as a secondary efficacy endpoint in kidney transplant clinical trials.

Key Points: 
  • This significant qualification means that the iBox Scoring System, which supports the evaluation of novel immunosuppressive therapy (IST) applications with EMA, will soon be available to be used as a secondary efficacy endpoint in kidney transplant clinical trials.
  • The draft qualification opinion is going through a public consultation stage through Nov. 17, 2022.
  • Improving the long-term outcomes in kidney transplant recipients is the ultimate goal and, as such, the qualification of the iBox Scoring System has been TTC's primary initiative since its inception in 2017.
  • "Veloxis is proud to be a part of the Transplant Therapeutics Consortium and the incredible work to achieve draft qualification opinion status for the iBox Scoring System," says Mark Hensley, CEO of Veloxis.

CareDx Announces Cibiltech Initiates CIBIL Study Using iBox Artificial Intelligence to Monitor Kidney Transplant Patients

Retrieved on: 
木曜日, 3月 3, 2022
Patient, DNA, Annual report, SAN, Survival, Precision medicine, Medtech, SEC, Transplant, CEO, IBox, Clinical trial, Caregiver, Outcome, CIBIL, Technology, Partnership, Health, Nasdaq, Probability, GLOBE, Dentistry, Pharmaceutical industry

We look forward to the results of both CIBIL and OKRA, and to making iBox more widely available to clinicians in the United States as an additional clinical tool.

Key Points: 
  • We look forward to the results of both CIBIL and OKRA, and to making iBox more widely available to clinicians in the United States as an additional clinical tool.
  • CareDx is a minority owner of Cibiltech and holds exclusive rights to commercialize iBox in the United States.
  • We are excited to initiate the CIBIL study to assess the clinical and health economic benefits of using the iBox AI algorithm as an early intervention monitoring tool for kidney transplant patients worldwide, said Stephane Tholander, CEO of Cibiltech.
  • CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Cibiltech announces the first patient enrolled in its international clinical trial for monitoring kidney transplant patients using artificial intelligence

Retrieved on: 
木曜日, 2月 24, 2022
Technology, Biotechnology, Health, Other Health, Surgery, Other Science, Other Technology, Research, Medical Devices, Software, Hospitals, Science, Data Management, Clinical Trials, Saint Louis Hospital (Bangkok), Physician, Algorithm, Probability, IBox, IIA, Clinical trial, MDR, CIBIL, Adoption, Software, INSERM, Decision-making, Patient, AI, Technology, Survival, Solution, CEO, Hospital, Medical device, Dentistry

Cibiltech announced today that the first patient has been enrolled in the CIBIL clinical trial Clinical Impact of the iBox as an early Intervention tool.

Key Points: 
  • Cibiltech announced today that the first patient has been enrolled in the CIBIL clinical trial Clinical Impact of the iBox as an early Intervention tool.
  • A prospective randomized controlled trial to assess the use of a software predicting allograft survival in the follow-up of kidney transplanted patients (NCT05112315).
  • This marks the beginning of this first-of-its-kind clinical trial conducted in Europe evaluating a digital health solution.
  • The CIBIL study aims to provide clinical and health economic evidence to allow further deployment of Predigraft in Europe.

Fun Spot America to Reveal ArieForce One Roller Coaster at IAAPA Expo

Retrieved on: 
火曜日, 11月 16, 2021
Zero, Roller coaster elements, Animal Liberation Press Office, Orange County Convention Center, Press, Fun Spot America Theme Parks, IAAPA, Weightlessness, Element, GLOBE, HUGE, IBox, RMC, Rocky, Amusement park, Nightclub

We will have you believing youre traveling into space with all of the airtime moments and weightlessness this RMC coaster provides, said Fun Spot America CEO and Owner, John Arie Jr.

Key Points: 
  • We will have you believing youre traveling into space with all of the airtime moments and weightlessness this RMC coaster provides, said Fun Spot America CEO and Owner, John Arie Jr.
  • As a one-of-a-kind roller coaster, custom designed to the topography and layout of Fun Spot Atlanta, no other RMC roller coaster has this combination of elements.
  • To set up personal interviews with John Arie, Jr or other Fun Spot America representatives during the busy IAAPA week, please email John Chidester at [email protected] or call, (812) 319-2055.
  • The Press Office opens at 9 a.m. For more information on Fun Spot America, visit Fun-Spot.com .